ATE359830T1 - Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten - Google Patents
Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugatenInfo
- Publication number
- ATE359830T1 ATE359830T1 AT93309720T AT93309720T ATE359830T1 AT E359830 T1 ATE359830 T1 AT E359830T1 AT 93309720 T AT93309720 T AT 93309720T AT 93309720 T AT93309720 T AT 93309720T AT E359830 T1 ATE359830 T1 AT E359830T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugates
- molocules
- chemically defined
- defined non
- chemically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Polyesters Or Polycarbonates (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/118,055 US6060056A (en) | 1991-02-08 | 1993-09-08 | Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule |
| US14259893A | 1993-10-22 | 1993-10-22 | |
| US08/152,506 US5552391A (en) | 1990-01-16 | 1993-11-15 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| EP93309288 | 1993-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359830T1 true ATE359830T1 (de) | 2007-05-15 |
Family
ID=38015477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93309720T ATE359830T1 (de) | 1993-09-08 | 1993-12-03 | Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP0642798B1 (de) |
| AT (1) | ATE359830T1 (de) |
| DE (1) | DE69334133T2 (de) |
| DK (1) | DK0642798T3 (de) |
| ES (1) | ES2282988T3 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| KR100361933B1 (ko) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
| ES2282988T3 (es) * | 1993-09-08 | 2007-10-16 | La Jolla Pharmaceutical Company | Moleculas plataforma de valencia no polimericas,. |
| US5874409A (en) * | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| US6410775B1 (en) | 1995-06-07 | 2002-06-25 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| CN1166172A (zh) * | 1995-08-03 | 1997-11-26 | 达德化学系统公司 | 奎尼定缀合物及其在免疫测定中的应用 |
| KR20000016414A (ko) * | 1996-06-06 | 2000-03-25 | 와이즈먼 앤드루 | Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법 |
| EP0855403A1 (de) * | 1996-06-10 | 1998-07-29 | Laboratory of Molecular Biophotonics | Photosplatbare zyklische oligonukleotide |
| US7094943B2 (en) * | 1998-04-27 | 2006-08-22 | Hubert Köster | Solution phase biopolymer synthesis |
| US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
| US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
| US6399578B1 (en) * | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| CN1762990A (zh) * | 1999-06-08 | 2006-04-26 | 拉卓拉药物公司 | 包含氨基氧基的化合价平台分子 |
| MXPA02005236A (es) * | 1999-11-28 | 2004-03-19 | Jolla Pharma | Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos. |
| WO2001093914A2 (en) * | 2000-06-08 | 2001-12-13 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| US20110300150A1 (en) * | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2524586B2 (ja) * | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
| US4904582A (en) * | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5162515A (en) * | 1990-01-16 | 1992-11-10 | La Jolla Pharmaceutical Company | Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus |
| US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| ES2282988T3 (es) * | 1993-09-08 | 2007-10-16 | La Jolla Pharmaceutical Company | Moleculas plataforma de valencia no polimericas,. |
-
1993
- 1993-12-03 ES ES93309720T patent/ES2282988T3/es not_active Expired - Lifetime
- 1993-12-03 EP EP93309720A patent/EP0642798B1/de not_active Expired - Lifetime
- 1993-12-03 DK DK93309720T patent/DK0642798T3/da active
- 1993-12-03 DE DE69334133T patent/DE69334133T2/de not_active Expired - Fee Related
- 1993-12-03 AT AT93309720T patent/ATE359830T1/de not_active IP Right Cessation
- 1993-12-03 EP EP07004965A patent/EP1808183A3/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0642798A2 (de) | 1995-03-15 |
| EP1808183A2 (de) | 2007-07-18 |
| DE69334133T2 (de) | 2007-12-27 |
| EP0642798B1 (de) | 2007-04-18 |
| HK1014240A1 (en) | 1999-09-24 |
| ES2282988T3 (es) | 2007-10-16 |
| EP0642798A3 (de) | 1998-09-16 |
| EP1808183A3 (de) | 2009-07-01 |
| DE69334133D1 (de) | 2007-05-31 |
| DK0642798T3 (da) | 2007-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2171434A1 (en) | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | |
| ATE359830T1 (de) | Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten | |
| DE69834693D1 (de) | Zusammensetzung zur behandlung von elastischen polyurethanfasern und die damit behandelten fasern | |
| DE69533634D1 (de) | Geranylgeranyldiphosphate-Synthase und diese kodierende DNA | |
| HUP9901993A3 (en) | Substituted aryl or heteroarylamides having retinoid-like biological activity | |
| EP0744894A4 (de) | Sich selbst zusammensetzende multimere nukleinsäuregebilde | |
| FI953812A7 (fi) | Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja | |
| DE69401661D1 (de) | Nukleinsaeure-analog testverfahren | |
| DE69637156D1 (de) | Dna-molekül, herstellung und verwendung in der gentherapie | |
| DE69401230D1 (de) | Verwendung von Polyurethanen, die funktionelle Carboxylatogruppe enthalt, zur Haarfestigung | |
| DE69019886D1 (de) | Katheter und Instrumentarium zur extrakorporalen Zirkulation. | |
| DE69407870D1 (de) | Fluorierungskatalysator und Fluorierungsverfahren | |
| ATE218355T1 (de) | Verwendung von mycobacterium zur tumorbehandlung | |
| FI953602A7 (fi) | Raktori jäteveden biologiseen puhdistamiseen | |
| DE59203610D1 (de) | Reaktor zur Durchführung biologischer Reaktionen mittels Biokatalysatoren. | |
| DE69714504D1 (de) | Benzothiopene, diese enthaltende Zubereitungen und Verfahren | |
| DE69422716D1 (de) | Methode zur verbesserung der oxydation und ammoxydationskatalysatoren | |
| DE59407529D1 (de) | Weichmachende und hydrophobierende Nachgerbstoffe | |
| NO900696D0 (no) | Fremgangsmaate og anordning for biologisk behandling omfattende nitrifisering og denitrifisering av avloepsvann. | |
| DE69431825D1 (de) | Delta-9 Desaturase und dafür kodierendes Gen | |
| DE69331630D1 (de) | Verfahren zur inaktivierung von nukleotidsequenzen und dafür verwendbare metallchelate | |
| EP0749312A4 (de) | DIROFILARIA IMMITIS - Gp29 - PROTEINE, NUKLEINSÄUREMOLEKÜLE UND IHRE VERWENDUNGEN | |
| ATE202130T1 (de) | Behandelte kohlenstoffartige zusammensetzungen und verbesserte polymerzusammensetzungen | |
| DE69431544D1 (de) | Biochemischer Analysator und Inkubator dafür | |
| DE69130845D1 (de) | HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0642798 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |